… aspirin for secondary prevention of cardiovascular disease (… ), and clopidogrel as an alternative
in case of aspirin resistance (IB … clopidogrel may be considered in preference to aspirin in …

… dual antiplatelet therapy (DAPT) with clopidogrel-aspirin (CA) is more effective at preventing
early vascular events than aspirin monotherapy (AM) in patients with acute minor stroke or a …

… in patients with stable cardiovascular disease. The main strength in comparison with previous
analyses is that the study incorporates evidence not only with clopidogrel … , clopidogrel is …

… We provide further evidence to support this recommendation, as our rankings suggest
clopidogrel and aspirin was the best treatment in preventing recurrent strokes and death, both at …

… These findings are now reflected in the most recent guidelines (Table 1), which recommend
a shortened duration of DAPT, followed by clopidogrel monotherapy without aspirin, as the …

… secondary prevention medication for patients with CABG to maintain the benefits of
revascularization and prevent major adverse cardiovascular events. However, patients treated with …

… vascular events, or all-cause death within 90 days between the … For adverse events, similar
rates of symptomatic intracranial … Clopidogrel plus aspirin versus aspirin alone for preventing …

… including cardiovascular, ischaemic limb and bleeding events … to aspirin antiplatelet therapy
in coronary artery disease, and … clopidogrel antiplatelet therapy in peripheral arterial disease …

… aspirin monotherapy for secondary prevention in patients with the established atherosclerotic
vascular disease … compared aspirin with clopidogrel while 4 studies compared aspirin with …

… and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with …
stable coronary artery disease. The open-label STOPDAPT 2 study focused on patients treated …